| GTO ID | GTC2953 |
| Trial ID | NCT05266950 |
| Disease | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Altered gene | CI-135 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CI-135 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia |
| Year | 2022 |
| Country | China |
| Company sponsor | Beijing Boren Hospital |
| Other ID(s) | BRYY-IIT-LCYJ-2021-018 |
| Cohort 1 | |||||||||||||
|
|||||||||||||